structuretx.com - GPCR Net Assets per Single Share

Graphic logo of Structure Therapeutics (GPCR)

Structure Therapeutics (GPCR) revenue is based on the implementation of advanced therapy methods, as demonstrated by the price chart on the GURU.Markets exchange, where the indicator stands at 19.14. The company develops innovative oral medications for diabetes and obesity, relying on licenses and grants. The business is currently in a phase of active R&D growth, rendering it independent of general economic cycles.

Structure Therapeutics Inc (GPCR): Share Book Value from 04/28/2023 to 10/27/2026

structuretx.com - analytical breakdowns and key metrics (GPCR)

- price and consensus price forecast:
Stock Price Structure Pharma|GPCR - Consensus Target
- market capitalization data:
Market Value Structure Therapeutics Inc.|GPCR - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Structure Therapeutics|GPCR - Net Asset Value|Market Capitalization to Book Value Ratio structuretx.com|GPCR - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Structure Therapeutics|GPCR - Long-Term Debt to Capital|Short-Term Debt to Equity Structure Therapeutics Inc.|GPCR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Structure Therapeutics Inc.
Fundamental company valuation:Structure Pharma - GPCR
Manufactured products of Structure Therapeutics Inc.

For Structure Therapeutics (GPCR), the book value per share serves as an indicator of the real value of assets minus liabilities. By analyzing the historical book value per share, an investor determines the fundamental price basis stripped of market noise. Growth in this metric confirms the capitalization of internal resources. For this developer of oral GLP-1s, this reflects the resource base necessary to capture the inelastic obesity therapy market. This metric allows for an assessment of the company's resilience prior to the commercialization of its revolutionary product.

Competitors of Structure Therapeutics (GPCR)

ASND: Book Value per Share|MDGL: Accounting Value per Share|Net Assets per Single Share Corcept Therapeutics CORT|RYTM (rhythmtx.com) - Accounting Value of a Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|AGIO (Agios Pharmaceuticals Inc) - Net Assets per Single Share|MiMedx Corp (MDXG) - Accounting Value per Share|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS